Strategies for Updated Treatment Options for IPF
|
|
- Prosper Hicks
- 5 years ago
- Views:
Transcription
1 Strategies for Updated Treatment Options for IPF Paul W. Noble, MD Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine Professor and Chair Department of Medicine Director, Women's Guild Lung Institute Cedars-Sinai Medical Center Los Angeles, California Paul W. Noble, MD, has a financial interest/relationship or affiliation in the form of: Consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Genentech, Inc./F. Hoffmann-La Roche Ltd.; GlaxoSmithKline; and InterMune. Clinical Insights for Improving IPF Recognition and Diagnosis 1
2 Rachel: 61 Year Old With Persistent Cough and Dyspnea MEDICAL FORM Presenting Complaint Persistent cough Mild exercise intolerance No fever, chills, weight loss Medical History GERD Never smoker No significant exposures (eg, mold, bird, or drug) Medications Esomeprazole 40 mg/d oral Examination Notes BP: 130/80 Pulse: 72 Chest: Bibasilar crackles CV: Regular rate and rhythm, no M/R/G Abd: Soft, non tender, non obese Ext: No cyanosis/clubbing/or edema PFT at Presentation FVC 3.3 L 68% FEV L 90% FEV 1 /FVC 0.91 TLC % DLCO % Abd: abdomen; DLCO: diffusing capacity of the lung for carbon monoxide; Ext: extremities; FEV 1 : forced expiratory volume in 1 second; FVC: forced vital capacity; GERD: gastroesophageal reflux disease; M/R/G: murmurs, rubs, and gallops; TLC: total lung capacity. Distinguishing Dyspnea: IPF Prevalence 1 3 COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary fibrosis. 1. Raghu G et al. Resp Crit Care Med. 2006;174: Go AS et al. Circulation. 2013;127:e6 e Wheaton AG et al. MMWR Morb Mortal Wkly Rep. 2015;64:
3 Increasing Prevalence of IPF 1 Medicare Beneficiaries Age 65 y Median survival = 3.8 years Factors associated with lower survival Age, index year, male gender 1. Raghu G et al. Lancet Respir Med. 2014;2: Classification of Diffuse Parenchymal Lung Disease 1 AIP: acute interstitial pneumonia; COP: cryptogenic organizing pneumonia; DIP: desquamative interstitial pneumonia; DPLD: diffuse parenchymal lung disease; IIP: idiopathic interstitial pneumonia; LAM: lymphangioleiomyomatosis; LCG: Langerhans cell granulomatosis; LIP: lymphocytic interstitial pneumonia; NIP: nonspecific interstitial pneumonia; RB ILD: respiratory bronchiolitis interstitial lung disease. 1. American Thoracic Society; European Respiratory Society (ATS/ERS). Am J Respir Crit Care Med. 2002;165:
4 Updated Consensus Statement: Diagnostic Requirements for IPF 1,2 Diagnosis of IPF requires 1.Exclusion of other known causes of ILD 2.Presence of UIP pattern on HRCT (in patients without surgical biopsy) 3.An HRCT pattern of definite/possible UIP with a surgical lung biopsy showing definite/probable UIP HRCT: high resolution computed tomography; UIP: usual interstitial pneumonia. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: ATS/ERS. Am J Respir Crit Care Med. 2000;161(2 Pt 1): Clinical Tools for Diagnosis 1 Clinical History and physical PFT Lab Raise suspicion that ILD is present Identify the cause of the disease Infection Systemic disorders Exposures (eg, occupational, environment, hobby) Idiopathic 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183:
5 Radiographic Tools for Diagnosis 1 Radiographic HRCT: allows detailed evaluation of the lung parenchyma HRCT Features Ground glass attenuation Honeycombing/cysts Lines/reticular thickening Consolidation Nodules Decreased lung attenuation HRCT Distribution Upper Lower Central Peripheral Diffuse/bilateral 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Role of HRCT in Diagnosing UIP 1 UIP Pattern (All 4 Features) Subpleural, basal predominance Reticular abnormality Honeycombing with/without traction bronchiectasis Absence of features listed as inconsistent with UIP (column 3) Possible UIP (All 3 Features) Subpleural, basal predominance Reticular abnormality Absence of features listed as inconsistent with UIP (column 3) Inconsistent With UIP (Any) Upper or mid lung predominance Peribronchovascular predominance Extensive ground glass abnormality (extent > reticular abnormality) Profuse micronodules (bilateral, predominantly upper lobe) Discrete cysts (multiple, bilateral, away from areas of honeycombing) Diffuse mosaic attenuation/ air trapping (bilateral, in 3 lobes) Consolidation in bronchopulmonary segment(s)/lobe(s) 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183:
6 Rachel: 61 Year Old Female With Persistent Cough and Dyspnea PFT at Presentation FVC 3.3 L 68% FEV L 90% FEV 1 /FVC 0.91 TLC % DLCO % Test Results and Next Steps Her chest x ray is markedly abnormal The lung volumes are very small or restricted And there are reticular infiltrates that are worse on the periphery and perhaps the lower lobes For a more detailed evaluation of the lung parenchyma, we need to order a high resolution CT scan Rachel s HRCT 1 1. Image courtesy of Steven Nathan, MD. 6
7 Nonspecific Interstitial Pneumonia 1 1. Image courtesy of Navdeep Singh, MD. Chronic Hypersensitivity Pneumonitis 1 Mosaic Ground glass Air trapping 1. Image courtesy of Kevin Flaherty, MD. 7
8 Histologic Tools for Diagnosis 1,2 Histology Bronchoscopy Surgical lung biopsy UIP Pattern Marked fibrosis/architectural distortion honeycombing, predominantly subpleural/paraseptal Patchy fibrosis Fibroblastic foci Absence of features to suggest alternative diagnosis 1. Images courtesy of Steven Nathan, MD. 2. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Interstitial Lung Disease Diagnostic Team Clinician Radiologist Pathologist Communication among multidisciplinary team members is essential for an accurate diagnosis 8
9 Having a Conversation With the Patient Newly Diagnosed With IPF Spend adequate time to explain the prognosis and assess patient's preferences and values Burden and morbidity of IPF can be emotionally overwhelming and will likely impact family members as well Each individual patient with IPF is different; consider physiology, exercise tolerance, radiology, and pathology when choosing a course of treatment Patients who are at increased risk of mortality should be referred for lung transplantation early in the course Monitoring Patients With IPF for Disease Progression Every 3 to 4 months: PFT 6MWD (distance/nadir saturation) O 2 requirement Comorbidities Consider dyspnea questionnaire (UCSD) HRCT Annually or when suspicion for clinical worsening 6MWD: 6 minute walk distance; USCD: University of California, San Diego. 9
10 Shared Decision Making in IPF Treatment Review of Rachel s Case 61 year old female with ILD discovered through workup for cough and dyspnea Rachel s PFT showed restrictive lung disease with decreased gas transfer Patient was diagnosed with IPF Next step: Should we consider initiating therapy for IPF? 10
11 Breakthroughs in the Treatment of IPF Therapy Nintedanib Pirfenidone Trial Name INPULSIS ASCEND Both therapies were FDA approved on October 15, 2014, for treatment of IPF 2015 IPF guidelines indicate Conditional recommendation for use of nintedanib and pirfenidone (moderate confidence in effect estimates) 1 1. Raghu G et al. Am J Respir Crit Care Med. 2015;192(2):e3 e19. Nintedanib: INPULSIS 1 and INPULSIS 2 Trial Design 1 SGRQ: St. George s Respiratory Questionnaire. 1. Richeldi L et al. N Engl J Med. 2014;370:
12 INPULSIS Primary Endpoint: Adjusted Annual Rate of Decline in FVC 1 1. Richeldi L et al. N Engl J Med. 2014;370: INPULSIS Secondary Endpoint: Adjusted Mean Change From Baseline in Total SGRQ Score Over 52 Weeks 1 Study Nintedanib Placebo INPULSIS INPULSIS Difference, Nintedanib vs Placebo (95% CI) 0.05 ( 2.50 to 2.40) 2.69 ( 4.95 to 0.43) P Richeldi L et al. N Engl J Med. 2014;370:
13 INPULSIS: Time to First Investigator Reported Acute Exacerbation 1 INPULSIS 1 INPULSIS 2 1. Richeldi L et al. N Engl J Med. 2014;370: INPULSIS: Treatment Emergent Adverse Events 1 Diarrhea (~62% vs 18%) and nausea (~23% vs 6%) more common in nintedanib group than in the placebo group Event Nintedanib (n = 309) INPULSIS 1 Placebo (n = 204) Nintedanib (n = 329) INPULSIS 2 Placebo (n = 219) Any AE 96.4% 88.7% 94.5% 90.4% Any AE, excluding progression of IPF 95.8% 87.7% 94.5% 90.0% Severe AEs 26.2% 18.1% 28.3% 28.3% Serious AEs 31.1% 27.0% 29.8% 32.9% Fatal AEs 3.9% 4.9% 7.6% 9.6% AEs leading to treatment D/C 21.0% 10.8% 17.6% 15.1% 1. Richeldi L et al. N Engl J Med. 2014;370:
14 FDA Approval of Nintedanib 1 Approved October 15, 2014, for the treatment of IPF Liver function tests required prior to treatment and should be evaluated every 3 months in first year Dosage and administration 150 mg twice daily with food Take each dose approximately 12 h apart Adverse reactions? Consider temporary dose reduction to 100 mg, temporary interruption, or discontinuation 1. Ofev (nintedanib) Prescribing Information. ingelheim.com/biwebaccess/ ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing+Information/PIs/Ofev/ofev.pdf. Accessed July 24, Effect of Nintedanib on Patients With Baseline FVC >90% 1 Annual Rate of Decline in FVC by Baseline FVC 90% Predicted Patients with marginally impaired FVC at baseline might benefit from treatment with nintedanib 1. Kolb M et al. American Thoracic Society 2015 International Conference (ATS 2015). Abstract A
15 Nintedanib: Update From European Respiratory Society (ERS) International Congress Data from interim analysis of INPULSIS extension trial (INPULSIS ON) showed efficacy and safety of nintedanib is sustained long term (2 years) Effect of nintedanib on mean change from baseline in FVC at wk 48 of INPULSIS ON was comparable to that seen at 52 wk in INPULSIS trial: INPULSIS ON:» 87 ml for all patients» 96.4 ml for patients continuing treatment with nintedanib in extension trial» 73.1 ml for patients initiating treatment with nintedanib INPULSIS (pooled data from INPULSIS 1 and 2): 88.9 ml (nintedanib) vs ml (placebo) 1. Crestani B et al. European Respiratory Society International Congress 2015 (ERS 2015). Abstract OA4495. Pirfenidone: ASCEND Trial Design 1 PFS: progression free survival. 1. King TE Jr et al. N Engl J Med. 2014;370:
16 ASCEND: Primary Efficacy Analysis 1 Absolute difference 2.5% 7.9% 12.3% 15.3% Relative difference 54.0% 58.0% 57.8% 47.9% Rank ANCOVA P <.001 <.001 <.001 <.001 ANCOVA: analysis of covariance. 1. King TE Jr et al. N Engl J Med. 2014;370: ASCEND: Secondary Endpoints (6MWD and PFS) 1 1. King TE Jr et al. N Engl J Med. 2014;370:
17 ASCEND and CAPACITY: Mortality 1 Variable Pirfenidone Placebo HR (95% CI) P ASCEND Patients, n Death From any cause 4.0% 7.2% 0.55 ( ).10 Related to IPF 1.1% 2.5% 0.44 ( ).23 ASCEND and CAPACITY (pooled data) Patients, n Death From any cause 3.5% 6.7% 0.52 ( ).01 Related to IPF 1.1% 3.5% 0.32 ( ) King TE Jr et al. N Engl J Med. 2014;370: ASCEND: Treatment Emergent Adverse Events 1 Nausea (36% vs 13%) and rash (28% vs 9%) more common in pirfenidone group than placebo group Adverse events (AEs) generally mild to moderate severity, reversible, and without clinically significant sequelae Patients Pirfenidone (n = 278) Placebo (n = 277) Any AE 99.6% 98.2% Grade % 22.0% Grade 4 2.9% 5.1% Any serious AE 19.8% 24.9% IPF 2.5% 9.7% Treatment emergent all cause mortality 2.9% 5.4% Any AE leading to treatment discontinuation 14.4% 10.8% 1. King TE Jr et al. N Engl J Med. 2014;370:
18 FDA Approval of Pirfenidone 1 Approved October 15, 2014, for the treatment of IPF Liver function tests required prior to treatment and should be evaluated every 3 months in first year Dosage and administration 801 mg 3x daily with food (three 267 mg capsules per dose) Take each dose at the same time each day Initiate with titration» Days 1 7: one capsule 3x daily» Days 8 14: two capsules 3x daily» Days 15 onward: three capsules 3x daily Adverse reactions? Consider temporary dosage reduction, treatment interruption, or discontinuation 1. Esbriet (pirfenidone) Prescribing Information. Accessed July 24, Effect of Pirfenidone on Patients With 10% Decline in FVC in First 6 Months of Treatment a Outcomes During the Subsequent 6 Month Period After an Initial 10% Absolute Decline in %FVC 1 a Pooled data from ASCEND and CAPACITY. 1. Nathan SD et al. ATS Abstract A1016. Patients whose disease has progressed might benefit from continued treatment with pirfenidone 18
19 Pirfenidone: Update From ERS International Congress Kaplan Meier Plot of Treatment Emergent All Cause Mortality Through End of Study of All Randomized Patients 1. Nathan SJ et al. European Respiratory Society International Congress 2015 (ERS 2015). Abstract Engaging in a Shared Decision Making Process With Rachel, a 61 Year Old Patient With IPF Physician provides Treatment options Risks and benefits Mutually acceptable decision Patient provides Personal preferences Values and concerns Discuss the efficacy and safety of FDA approved therapies Listen to Rachel s preferences and concerns Focus on symptom control and management of comorbidities Set treatment expectations Look at the option of lung transplantation 19
20 Improving Comorbidity Management and Quality of Life Throughout the IPF Disease Continuum Will: 57 Year Old With Comorbid Disease 57 year old male Diagnosed with IPF ~3 y ago (CT scan and open lung biopsy) Medical history significant for depression, GERD, and pulmonary hypertension 20
21 IPF Comorbidities 1 Pulmonary Parenchymal lung disease Lung cancer COPD or emphysema Infections, such as aspergillomas Pulmonary vascular disease (eg, pulmonary embolus, PH) Other (eg, sleep apnea) Extrapulmonary Cardiac (eg, HFpEF, CAD) Endocrine (eg, diabetes mellitus, hypogonadism) Hematologic (eg, anemia, polycythemia) GI (eg, GERD) Psychiatric Musculoskeletal (eg, osteoporosis, deconditioning) Medications HFpER: heart failure with preserved ejection fraction; PH: pulmonary hypertension. 1. King C, Nathan SD. Curr Opin Pulm Med. 2013;19: GERD Treatment and Survival 1 Suggests that GERD could contribute to the rate of decline in patients with IPF 1. Lee JS et al. Am J Respir Crit Care Med. 2011;184:
22 GERD Management in IPF: ATS/ERS Recommendation IPF guidelines suggest that clinicians use regular antacid treatment for patients with IPF (conditional recommendation, very low confidence in effect estimates) 1 1. Raghu G et al. Am J Respir Crit Care Med. 2015;192(2):e3 e19. Prevalence of Pulmonary Hypertension in IPF 1 Concomitant PH and IPF significantly increases the likelihood of mortality or lung transplant RHC: right heart catheterization; RVSP: right ventricular systolic pressure. 1. Nathan SD, Cottin V. Eur Respir Monogr. 2012;57:
23 Treat IPF Patients for PH? 1 Ambrisentan, bosentan, and macitentan have been found nonefficacious or harmful STEP IPF Trial (Sildenafil) In patients with advanced IPF, the primary outcome variable (proportion of patients with 6MWD increase >20%) was not met However, arterial oxygenation, DLCO, dyspnea, and quality of life improved ATS/ERS guidelines suggest that clinicians not use sildenafil, for treatment of IPF (conditional recommendation against, moderate confidence in estimates of effect) 2 1. Zisman DA et al. N Engl J Med. 2010;363: Raghu G et al. Am J Respir Crit Care Med. 2015;192(2):e3 e19. Treat IPF Patients for PH? IPF patients should NOT be routinely treated for PH ATS/ERS Recommendation for PH Management 1 PH should not be treated in the majority of patients with IPF, but treatment may be a reasonable choice in a minority (weak recommendation, very lowquality evidence) In patients with moderate to severe PH (mpap >35 mmhg) documented by RHC, a trial of vasomodulatory therapy may be indicated 2015 updated guidelines note that reassessment of the previous recommendation was deferred 2 Is IPF with PH a distinct clinical phenotype (IPF PH)? Regardless, mortality risk is higher and lung transplantation should be discussed early mpap: mean pulmonary arterial pressure. 1. Raghu G et al. Am J Respir Crit Care Med. 2011;183: Raghu G et al. Am J Respir Crit Care Med. 2015;192(2):e3 e19. 23
24 IPF Impairs Patient s Quality of Life 1 Symptoms Dyspnea limited activity Fatigue/exhaustion Cough Dry, nagging, never satisfying Look for evidence of reflux and treat, as this may improve severe cough Outlook Hopeless, abandoned Frustrated, uneducated, embarrassed 1. heart failure/shortness of breath. Accessed July 22, Enroll patients in pulmonary rehabilitation and support groups Supportive Care for Patients With IPF Supportive Care Options Educate patients Refer to reliable sources Treatment of comorbid illness PH, GERD, OSA, CAD Prescribe O 2 Screen for resting/ nocturnal/exertional requirement Close monitoring of symptoms and pulmonary function Exercise Pulmonary rehabilitation OSA: obstructive sleep apnea. 24
25 Patient Centered Management 1 Informed, activated, participatory patient and family Patient centered, communicative healthcare provider Accessible, well organized, responsive healthcare system Improved communication Improved health outcomes 1. Epstein RM, Street RL Jr. National Cancer Institute, NIH Publication No Bethesda, MD: Will: Overcoming Barriers to Optimal IPF Management Initiate treatment An Action Plan for Will Notify if change in status/new symptoms occur Monitor oxygen desaturation to see if he needs supplemental oxygen Get educated Discuss transplant options and potential next steps Consider a support group Focus on things that he can still do Stay active, weight loss program if overweight Consider a pulmonary rehabilitation program Adhere to management plan, explaining his other options if he progresses Other medications Clinical trials Engaging the patient, his family, and his clinician in his care can lead to the best possible outcome 25
DIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationInterstitial Lung Disease (ILD)
Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
More informationSummary: Key Learning Points, Clinical Strategies, and Future Directions
Summary: Key Learning Points, Clinical Strategies, and Future Directions Introduction Idiopathic pulmonary fibrosis (IPF), a peripheral lobular fibrosis of unknown cause, is a chronic, progressive lung
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationNintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationNew Horizons The Future of IPF and ILD
New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationTherapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic
Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More information9/12/18. Emerging Challenges in Primary Care: Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis
Emerging Challenges in Primary Care: 2018 Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationChallenges in Pulmonary and Critical Care: 2018
Challenges in Pulmonary and Critical Care: 2018 Interstitial Lung Disease: Evolving Our Understanding of a Deadly Disease 1 Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Idiopathic Pulmonary Fibrosis Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationINHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)
THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationWim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.
nterstitial ungdiseases euven Department of pneumology Unit for interstitial lung diseases University Hospitals Leuven March 12 th 2015 Interstitial lung diseases state of the art Treatment of idiopathic
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationExperience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina
ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationRegulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.05 Subject: Ofev Page: 1 of 5 Last Review Date: March 17, 2017 Ofev Description Ofev (nintedanib)
More informationGuidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationAn earlier and more confident diagnosis of idiopathic pulmonary fibrosis
Eur Respir Rev 2012; 21: 124, 141 146 DOI: 10.1183/09059180.00000812 CopyrightßERS 2012 REVIEW: IPF An earlier and more confident diagnosis of idiopathic pulmonary fibrosis Roland M. du Bois ABSTRACT:
More informationNINTEDANIB MEDIA BACKGROUNDER
NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule
More informationIPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
More informationDr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham
Dr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham Types of Questions you Will Be Asked Rhetorical Participatory Disclosure of Relevant Financial
More informationNew Therapies and Trials in IPF
Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans
More informationIdiopathic Pulmonary of Care
Chapter 6.1 Living Medical etextbook A Digital Tool at the Point of Care From Projects In Knowledge Pulmonology Idiopathic Pulmonary Fibrosis @Point of Care IPF Case Study: Typical Presentation, Role of
More informationIDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management
IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management An ATS Pocket Publication This publication was produced in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. GUIDELINES
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationPresente e futuro della terapia della fibrosi polmonare idiopatica
Presente e futuro della terapia della fibrosi polmonare idiopatica Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp.
More informationESBRIET (pirfenidone) oral capsule and oral tablet OFEV (nintedanib) oral capsule
OFEV (nintedanib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationImaging: how to recognise idiopathic pulmonary fibrosis
REVIEW IDIOPATHIC PULMONARY FIBROSIS Imaging: how to recognise idiopathic pulmonary fibrosis Anand Devaraj Affiliations: Dept of Radiology, St George s Hospital, London, UK. Correspondence: Anand Devaraj,
More informationManagement of Idiopathic Pulmonary Fibrosis
Management of Idiopathic Pulmonary Fibrosis Robert Hallowell, M.D. December 22, 2015 Disclosures No financial disclosures What causes IPF? +? VEGF-R Airspace lining TNFa Fibrocytes PDGF Fibroblasts IL-1
More informationIPF - Inquadramento clinico
IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationLung Allograft Dysfunction
Lung Allograft Dysfunction Carlos S. Restrepo M.D. Ameya Baxi M.D. Department of Radiology University of Texas Health San Antonio Disclaimer: We do not have any conflict of interest or financial gain to
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationNational Jewish Health. Idiopathic Pulmonary Fibrosis: A Guide for Providers
National Jewish Health Idiopathic Pulmonary Fibrosis: A Guide for Providers Table of Contents National Jewish Health Materials were developed through a partnership between National Jewish Health and PVI,
More informationRadiologic pathologic discordance in biopsy-proven usual interstitial pneumonia
ERJ Express. Published on February 25, 2016 as doi: 10.1183/13993003.01680-2015 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Radiologic pathologic discordance in biopsy-proven usual interstitial pneumonia
More informationDaria Manos RSNA 2016 RC 401. https://medicine.dal.ca/departments/depar tment-sites/radiology/contact/faculty/dariamanos.html
Daria Manos RSNA 2016 RC 401 https://medicine.dal.ca/departments/depar tment-sites/radiology/contact/faculty/dariamanos.html STEP1: Is this fibrotic lung disease? STEP 2: Is this a UIP pattern? If yes:
More informationOctober 30, The Westin Princeton at Forrestal Village 201 Village Boulevard Princeton, NJ Marilyn Glassberg Csete, MD FACP, FCCP
October 3, 215 The Westin Princeton at Forrestal Village 21 Village Boulevard Princeton, NJ 854 Marilyn Glassberg Csete, MD FACP, FCCP Professor of Medicine, Surgery, and Pediatrics at the University of
More informationIdiopathic pulmonary fibrosis
Pharmacologic Treatments for Idiopathic Pulmonary Fibrosis This chronic disease has historically lacked an effective treatment option, but the FDA recently approved two: pirfenidone and nintedanib. This
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More informationCryptogenic Organizing Pneumonia Diagnosis Approach Based on a Clinical-Radiologic-Pathologic Consensus
Cryptogenic Organizing Pneumonia Diagnosis Approach Based on a Clinical-Radiologic-Pathologic Consensus Poster No.: C-1622 Congress: ECR 2012 Type: Scientific Exhibit Authors: C. Cordero Lares, E. Zorita
More informationUIP Possibile e Probabile
UIP Possibile e Probabile Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale San Giuseppe - Milano Current definition of IPF IPF is a distinct type
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationTriple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis
Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationPFF HEALTH CARE PROFESSIONAL WEBINAR SERIES. Welcome!
PFF HEALTH CARE PROFESSIONAL WEBINAR SERIES Welcome! AGENDA TOPICS Welcome & Introduction Dr. Gregory Cosgrove, MD Chief Medical Officer Pulmonary Fibrosis Foundation PFF Resources Dolly Kervitsky, RCP,
More informationJune 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference. Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2
June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2 Departments of Pulmonary Medicine 1 and Laboratory Medicine and Pathology 2 Mayo Clinic
More informationOfficial ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis
Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline Online Supplement Ganesh Raghu, Bram Rochwerg, Yuan
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationUnpaid scientific collaborator & advisor with Veracyte, Inc.
Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair
More informationT he diagnostic evaluation of a patient with
546 REVIEW SERIES Challenges in pulmonary fibrosis? 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias Michael B Gotway, Michelle M
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationUIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!
UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France CASE OVERVIEW This case highlights how a usual
More informationNAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis
NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis Mark J Rumbak, MD Division Director Pulmonary, Critical Care and Sleep Medicine Morsani College of Medicine University of South Florida, Tampa
More informationCADTH CDEC FINAL RECOMMENDATION
CADTH CDEC FINAL RECOMMENDATION NINTEDANIB (Ofev Boehringer Ingelheim Canada Ltd.) Indication: Idiopathic Pulmonary Fibrosis Recommendation: The CADTH Canadian Drug Expert Committee (CDEC) recommends that
More informationCriteria for confident HRCT diagnosis of usual interstitial pneumonia (UIP)
Criteria for confident HRCT diagnosis of usual interstitial pneumonia (UIP) Assem El Essawy (1) & Amr A. Nassef (٢) Abstract Identification of interstitial pneumonia (IP) was mainly based on histological
More informationDisclosures. IPF Medications: Practical Experience. Prednisone, Azathioprine, N acyetylcysteine. Case 1. Brett Ley, MD, MAS Assistant Professor, UCSF
IPF Medications: Practical Experience Disclosures Received speakers bureau honorarium from Roche/Genentech (makers of pirfenidone). Brett Ley, MD, MAS Assistant Professor, UCSF 67 y/o man 1 year cough
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationInterstitial Lung Disease ILD: Definition
Interstitial Lung Disease 2007 Paul F. Simonelli,, MD, PhD, FCCP Clinical Director Center for Interstitial Lung Disease Columbia University Medical Center 1. ILD is not one disorder ILD: Definition 2.
More informationRandomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
original article Randomized Trial of in Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* ABSTRACT Background has been suggested as a beneficial treatment for idiopathic
More informationSystemic lupus erythematosus (SLE): Pleuropulmonary Manifestations
08/30/10 09/26/10 Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations Camila Downey S. Universidad de Chile, School of Medicine, Year VII Harvard University, School of Medicine Sept 17,
More informationIdiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping
Idiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping K. R. Flaherty Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor,
More informationIdiopathic Pulmonary Fibrosis Treatable and Not Idiopathic
Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Brett Ley, MD University of California San Francisco CTS 1/26/18 Disclosures Speaker s bureau honorarium from Genentech (makers of pirfenidone)
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationIPF : Dalla Diagnosi alla Terapia
IV Forum di Pneumologia Interventistica Bologna 5-6 Giugno 2015 IPF : Dalla Diagnosi alla Terapia Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale
More informationNew Drug Evaluation: Pirfenidone capsules, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationTimely Topics in Pulmonary Medicine
Disclosures Timely Topics in Pulmonary Medicine I have nothing to disclose! Lorriana Leard, MD Associate Professor of Clinical Medicine Chief of Clinical Operations UCSF Pulmonary, Critical Care, Allergy
More informationThe radiological differential diagnosis of the UIP pattern
5th International Conference on Idiopathic Pulmonary Fibrosis, Modena, 2015, June 12th The radiological differential diagnosis of the UIP pattern Simon Walsh King s College Hospital Foundation Trust London,
More informationRole of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study
36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E
More informationEvaluating New Treatment Options
Evaluating New Treatment Options Steven D. Nathan, MD Clinical Practice Guideline Changes 211 ATS/ERS/JRS/ALAT Recommendations Treatment of IPF combines nonpharmacologic and pharmacologic strategies, and
More informationINVITED REVIEW SERIES: PULMONARY FIBROSIS SERIES EDITORS: MARTIN KOLB AND GERARD COX
INVITED REVIEW SERIES: PULMONARY FIBROSIS SERIES EDITORS: MARTIN KOLB AND GERARD COX Diagnosing fibrotic lung disease: When is high-resolution computed tomography sufficient to make a diagnosis of idiopathic
More information